THTX - Theratechnologies, Inc. Debt to Book Capitalization Ratio

Theratechnologies Inc. (THTX) efficiency relies on strict temperature control during the transport of immune agents to preserve their properties. Revenues are based on the sale of rare HIV drugs and the approval of oncology molecules, with a margin of 0.00. The available price action vector complements the profile of the company, which develops unique protein-based drugs for patients with metabolic disorders within a protected orphan niche.

This ratio compares total liabilities to net asset value, determining the extent to which the capital structure depends on borrowed funds. By analyzing the percentage of debt participation in the balance sheet capital, an investor can assess the resilience of Theratechnologies Inc. (THTX) to regulatory risks and raw material supply disruptions, where an increase in debt load amid geopolitical instability may indicate a decline in the financial autonomy of the biopharmaceutical business.